CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Azenta Life Sciences | February 28, 2023
On February 27, 2023, Azenta Life Sciences, a leading provider of life sciences solutions, announced the launch of its latest automated cryogenic storage system, the Cryo Store PicoTM. This new product is designed to store high-value biological samples used throughout various stages of the life sciences industry, from research and development to clinical use.
Azenta is already known for providing innovative automated cryogenic solutions such as the BioStore™ III Cryo and the CryoPod™ Carrier, and the Pico is the latest addition to its lineup. The product offers automated cryogenic solutions that are configured for laboratory and clinical procedures.
The Pico offers a variety of features for cell and gene therapy developers and manufacturers, including end-stage deployment in hospitals and clinics. It offers controlled access and traceability to support regulatory compliance with a compact footprint and is also user-friendly for laboratory personnel.
Interested parties can order the Pico now, and a live demonstration will take place at the Society for Laboratory Automation and Screening (SLAS) 2023 International Conference in San Diego, California.
Pico's Product Manager Erica Waller commented, "Pico takes our proven automation capabilities and scales it down for the lab or the clinic, bringing the sample integrity and process rigor of automation closer to the point of use,"
(Source – PR Newswire)
About Azenta Life Sciences
Azenta is a leading life sciences solutions provider that helps to accelerate the development and delivery of impactful therapies to market. The company offers a comprehensive suite of cold-chain sample management solutions and genomic services for areas such as clinical research, drug development and advanced cell therapies. These solutions are trusted by some of the top biotech, pharmaceutical, academic, and healthcare institutions worldwide. Headquartered in Chelmsford, MA, Azenta has a global presence with operations across Europe, North America, and Asia. The company is committed to providing reliable, innovative, and high-quality solutions to meet the needs of its clients in the life sciences industry.
MEDTECH, INDUSTRIAL IMPACT
Cybin | January 19, 2023
On January 18, 2023, Cybin Inc., a leading biopharmaceutical firm focused on advancing Psychedelics to Therapeutics®, announced the key findings from a feasibility study undertaken by its partner Kernel, which evaluated Kernel's Flow® wearable technology to assess ketamine's psychedelic effect on cerebral cortex hemodynamics. The findings of this Cybin-sponsored study are meant to guide the program's future direction.
The key highlights of the feasibility study are
It offered important proof-of-concept for Kernel Flow as a portable functional system that delivers real-time measurements of blood oxygenation changes in the brain linked with neural activity utilizing Time Domain Near Infrared Spectroscopy (TD-fNIRS).
Exhibited changes in functional brain biomarkers caused by ketamine that are related to potential therapeutic effects, including changes in cortical function associated with psychedelic experiences.
Compared to saline, ketamine reduces the global brain connectivity of the prefrontal region and decreases the brain-wide fractional amplitude of low-frequency fluctuations (fALFF). It has been proposed that fALFF is of particular functional significance within the default mode network, which has been demonstrated to be modulated by psychedelics and is associated with several neuropsychiatric conditions.
A model incorporating neurological and physiological metrics successfully predicted mystical experience scores on the Revised Mystical Experience Questionnaire, which has been shown to mediate reductions in depressive symptomatology in prior studies.
Displayed reliable pulse rate variability (PRV) and physiological measurements of pulse rate (PR) from TD-fNIRS recordings that correspond to those obtained from commercial external photoplethysmography sensors, thereby eliminating the need for external sensors to measure cardiac activity in future experiments.
Ketamine increased PR, decreased PRV, increased absolute oxy-hemoglobin concentrations and decreased deoxy-hemoglobin concentrations while increasing electrodermal activity (measured by an external sensor), providing additional physiological measures of the impact of the ketamine doses administered in the study.
The main goal of the feasibility study was to find out how people who had been given ketamine felt about wearing Kernel Flow while in an altered state of consciousness.
The feasibility study was granted FDA Investigational New Drug approval in October 2021 and US Institutional Review Board approval in January 2022.
Founded in 2019 and headquartered in Canada, Cybin is a biotechnology company that develops psychedelic pharmaceutical treatments for a variety of psychiatric and neurological disorders. It collaborates with a network of world-class partners and internationally recognized scientists to develop safe and effective treatments for patients dealing with a wide range of mental health conditions. The company is currently operating in the United States, Canada, the United Kingdom, Ireland, and the Netherlands.
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
GenScript | March 03, 2023
GenScript Biotech Corporation, a leading tools and services provider for life-science research, recently announced the expansion of its Singapore facility to provide a high-quality gene synthesis service. This expansion has added 976 square meters to the facility, bringing its total size to 3,500 square meters, making it the third-largest facility for GenScript globally. This development will also increase the staff at the Singapore facility to 150.
In February 2022, GenScript Asia-Pacific opened a recombinant protein production facility, which will now offer an advanced gene synthesis service. This expansion is a significant step towards GenScript's aim to provide top-notch services required for novel vaccine and therapeutic development in the life-sciences field.
The Singapore facility uses modernized, automated workstations that can synthesize more than 400 genes daily, ensuring precise measurement, eliminating human error, and providing a consistently high-quality product. The new facility's goal is to decrease project turnaround time for a more global mix of clients while maintaining customer data security. The new facility's capacity is dedicated to gene and cell therapy research and vaccine development programs.
GenScript's Life Science Group President, Dr. Ray Chen, commented, "We understand that global supply is a huge challenge, and we remain committed to expanding our reach to meet the increasing demand for our customers worldwide. At GenScript, we take great pride in our ability to provide reliable and efficient solutions to our customers, and we are fully committed to delivering on this promise. As we continue to expand our global footprint, we remain dedicated to providing the highest-quality products and services to our customers, wherever they may be located."
(Source – PR Newswire)
Founded in 2002, GenScript is a leading biotech firm. It has a global presence across the EU, North America, Greater China and Asia Pacific and has served more than 300,000 customers from over 160 countries and regions around the world. With more than 5,000 employees, it is dedicated to providing premier, convenient, and reliable products and services. The company strongly focuses on technology development, with over 100 patents and 270 patent applications in fields such as immunotherapy, synthetic biology, chemical synthesis, antibody design and bioinformatics. GenScript's products and services have been cited in 74,700 scientific papers worldwide as of June 2022. The company's vision is to become the most reliable biotech company in the world, working towards the betterment of human and environmental health through biotechnology.